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ABSTRACT
Objective Several pathogenic roles attributed over the
past two decades to either T helper (Th)1 or Th2 cells
are increasingly becoming associated with interleukin
(IL)-17 and most recently IL-9 signalling. However, the
implication of IL-9 in IBD has not been addressed so far.
Design We investigated the expression of IL-9 and
IL-9R by using peripheral blood, biopsies and surgical
samples. We addressed the functional role of IL-9
signalling by analysis of downstream effector proteins.
Using Caco-2 cell monolayers we followed the effect of
IL-9 on wound healing.
Results IL-9 mRNA expression was signiﬁcantly
increased in inﬂamed samples from patients with UC as
compared with controls. CD3+ T cells were major
IL-9-expressing cells and some polymorphonuclear
leucocytes (PMN) also expressed IL-9. IL-9 was
co-localised with the key Th9 transcription factors
interferon regulatory factor 4 and PU.1. Systemically, IL-9
was abundantly produced by activated peripheral blood
lymphocytes, whereas its receptor was overexpressed on
gut resident and circulating PMN. IL-9 stimulation of the
latter induced IL-8 production in a dose-dependent
manner and rendered PMN resistant to apoptosis
suggesting a functional role for IL-9R signalling in the
propagation of gut inﬂammation. Furthermore, IL-9R
was overexpressed on gut epithelial cells and IL-9
induced STAT5 activation in these cells. Moreover, IL-9
inhibited the growth of Caco-2 epithelial cell monolayers
in wound healing experiments.
Conclusions Our results provide evidence that IL-9 is
predominantly involved in the pathogenesis of UC
suggesting that targeting IL-9 might become a
therapeutic option for patients with UC.
INTRODUCTION
UC, the most common form of IBD, is a chronic
condition in which the overreacting immune system
drives a sustained epithelial damage of the gut in
response to microbial and environmental factors in
a genetically predisposed individual.1 2 Our under-
standing of IBD pathogenesis has proﬁted from
major advances in experimental animal models of
the disease and sequence analysis of susceptibility
genes.1–4 Based on patient data and the murine
oxazolone-induced colitis model, that drives a
Th2-like response, it has been proposed that epithe-
lial barrier damage in UC is driven by a T helper cell
(Th)2-like phenotype and interleukin (IL)-13 has
been associated with disease pathogenesis in UC.5 6
The identiﬁcation of the Th17 lineage of T
helper cells at the beginning of the century7 has
challenged the Th1-Th2 paradigm proposed by
Signiﬁcance of this study
What is already known on this subject?
▸ IBD is a chronic life-threatening condition
characterised by an overreacting immune
response in genetically susceptible individuals.
▸ Disease pathogenesis in UC, one of the two
major forms of IBD, has been attributed to an
altered Th2/Th17 response.
▸ Our previous work suggested a critical role for
interferon regulatory factor 4 (IRF4) in
controlling IL-17-dependent gut inﬂammation.
▸ IRF4 and PU.1 have been recently identiﬁed as
master transcription factors of the newly deﬁned
Th9 cells.
What are the new ﬁndings?
▸ IL-9 was highly expressed in UC correlating with
disease activity; the main source of IL-9 were
CD3+ T cells and multicolour
immunoﬂuorescence stainings demonstrated the
co-localisation of IL-9 with the Th9 transcription
factors IRF4 and PU.1 but not with the cytokines
IL-4 or IL-10.
▸ Stimulated peripheral blood lymphocytes from
patients with UC produced signiﬁcantly more IL-9
than control cells.
▸ Peripheral blood and lamina propria inﬁltrating
polymorphonuclear leucocytes expressed the
IL-9R; stimulation of blood polymorphonuclear
leucocytes with IL-9 resulted in a
dose-dependent production of IL-8 that (1)
could be blocked by anti-IL-9R antibodies and
(2) was accompanied by increased resistance of
polymorphonuclear leucocytes to apoptosis.
▸ IL-9 stimulation of freshly isolated
IL-9R-overexpressing epithelial cells led to STAT5
activation; anti-IL-9R blockade could prevent the
IL-9-induced growth delay of Caco-2 cell
monolayers in wound healing assays.
How might it impact on clinical practice in
the foreseeable future?
▸ IL-9 could represent a valuable tool in assessing
disease severity and its signalling pathways may
become novel therapeutic targets in UC.
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Mosmann and Coffman in 19868 9 opening new avenues for
dissecting molecular patterns in cellular immunology. It was
soon demonstrated that Th17 cells were critically involved in
host defence and disease pathogenesis in tissues like the gut, the
lung and the brain.7 10 At present, it is accepted that UC patho-
genesis is driven by a modiﬁed Th2 response mixed with a
Th17 cell-sustained inﬂammation.10 11 Even more recently
however, new subsets of Th cells, for example, Th912 and
Th22,13 have been deﬁned but their roles in gut pathology
remained unaddressed.
IL-9 has been discovered as a potent growth factor for T cell
lines and mast cells and its role in allergic and asthmatic conditions
has been largely characterised over the past decade.14 15 Initially
viewed as a Th2 cytokine, and thereafter associated with Th17
responses, IL-9 has been recently proposed to be the deﬁning cyto-
kine for a new lineage of CD4 T cells, the Th9 cells, which add-
itionally produce high levels of IL-10 but none of the Th1-speciﬁc,
Th2-speciﬁc and Th17-speciﬁc cytokines.16 17 The signalling of
the novel Th9 cells has been linked to the transcriptional pro-
grammes of STAT6,16–18 interferon regulatory factor (IRF) 419
and PU.1.20 Nevertheless, our previous studies demonstrated a
critical role for IRF4 in the pathogenesis of IBD.21 22
In the present study, we investigated the role of IL-9 and the
Th9 transcription factors IRF4 and PU.1 in UC. Our ﬁndings
suggest that IL-9 is predominantly involved in the pathogenesis
of the disease.
MATERIALS AND METHODS
The collection of human samples was approved by the local
Ethical Committee and the Review Board of the University of
Erlangen-Nuremberg, and each patient gave written informed
consent (number 4032/KFO/2011, 4032/2009). Materials and
methods are available as online supplementary ﬁle 1.
RESULTS
IL-9 mRNA is signiﬁcantly overexpressed in mucosal
biopsies of the inﬂamed gut in UC
We ﬁrst assessed colonic biopsies from patients with UC and
controls by quantitative real-time PCR for IL-9 mRNA expres-
sion. In these studies, mucosal inﬂammation was classiﬁed
according to previously described criteria: inﬂammation score
(IS)0 (absent inﬂammation)—IS3 (severe inﬂammation).23 It was
found that the level of IL-9 mRNA expression increased with
increasing IS in UC (ﬁgure 1A). In addition, the levels of other
proinﬂammatory cytokines (such as IL-17A and IL-6) were also
increased in severely inﬂamed UC mucosa. However, IL-9 levels
in the ileum and colon of patients with Crohn’s disease were
not signiﬁcantly upregulated (ﬁgure 1A). Moreover, in contrast
to IL-9, mRNA levels for IL-4, IL-6, IL-10, IL-13, IL-17A,
IL-21, IFNγ, TGF-β and TNFα were detected in patients with
UC with lower inﬂammation and, albeit at lower levels, also in
controls (ﬁgure 1A). Highest correlations between IL-9 mRNA
levels and levels of IL-6 (R=0.49; p<0.001), IL-13 (R=0.47;
p<0.001) and IL-17A (R=0.47; p<0.001) were observed
(ﬁgure 1B). In addition, a correlation between the expression
levels of the inﬂammatory protein marker S100A8 and IL-9 was
noted (R=0.57; p<0.001; ﬁgure 1B).
CD3+ T cells are key IL-9-expressing cells in the
inﬂamed gut of patients with UC
Next, we systematically focused on investigating mildly (ie, IS1)
as well as severely (ie, IS3) inﬂamed material along with control
samples. Parafﬁn sections of gut specimens from patients with
UC with mild and severe inﬂammation and non-inﬂammatory
controls were ﬁrst stained with antibodies against IL-9
(ﬁgure 2A). Quantiﬁcation of these data showed a signiﬁcantly
increased number of IL-9-expressing cells in severe versus mild
inﬂammation as well as in both groups versus the control group
(ﬁgure 2B). Furthermore, two-colour immunoﬂuorescence stain-
ings of parafﬁn sections revealed that patients with severe
inﬂammation had signiﬁcantly increased numbers of CD3+
IL-9-expressing cells compared with patients with mild inﬂam-
mation and the control group, respectively (ﬁgure 2C, D).
Although CD3+ cells accounted for more than 75% of the
IL-9-expressing cells in the inﬂamed gut (ﬁgure 2E), some
IL-9-expressing cells were CD3−. To address the nature of these
cells, we stained gut sections with IS3 for IL-9 and myeloperoxi-
dase, a speciﬁc marker for polymorphonuclear leucocytes
(PMN) that often dominate the acute inﬂammatory inﬁltrate in
UC. Our results showed that myeloperoxidase positive PMN
can express IL-9 in UC (see online supplementary ﬁgure S1A).
Upregulation of the key Th9 transcription
factors IRF4 and PU.1 in UC
IL-9 expression by Th9 cells was previously reported to be depend-
ent on the transcription factors IRF419 and PU.1.20 We found that
mRNA expression levels of IRF4 and PU.1 generally increased
with increasing inﬂammation in UC (ﬁgure 3A). Moreover, patients
with severe disease expressed signiﬁcantly more IRF4 and PU.1
compared with controls which showed lower expression. Within
individual cells IL-9 co-localised with each of the two key transcrip-
tion factors of the Th9 cells, namely IRF4 and PU.1, respectively
(ﬁgure 3B, C). The number of IRF4+ IL-9-expressing cells and
PU.1+ IL-9-expressing cells was signiﬁcantly increased in patients
with severe (ie, IS3) versus mild (ie, IS1) disease as well as in both
groups versus controls (ﬁgure 3B, C).
To functionally address the role of IRF4 for IL-9 production
in UC, we isolated peripheral blood lymphocytes of patients
with UC and cultured them under Th9 polarising conditions.
We found that compared with non-polarised cells which only
had marginal levels of IL-9 expression, as many as 6% of the
Th9 polarised cells expressed IL-9 in patients with UC
(ﬁgure 4A). Moreover, we observed that 25% of the polarised
CD3+ IRF4+ cells expressed IL-9 (ﬁgure 4A). We additionally
performed three-colour immunoﬂuorescence stainings on IS3
gut biopsies and found that IL-9 and IRF4 were coexpressed in
CD3+ cells (ﬁgure 4B), consistent with the idea that IRF4 acts
as a key transcription factor for the generation of IL-9 in the
inﬂamed gut of patients with UC. IL-9 has been previously
found to be coexpressed with IL-10 in murine CD3+ T cells16
17 or with IL-4 in murine invariable natural killer (NK)T cells,24
respectively. To address the expression proﬁle of these cytokines
in IL-9-expressing cells, we stained freshly isolated lamina
propria cells from inﬂamed UC tissue with antibodies to CD3,
Vα24-Jα18 (invariant NKT cells marker), IL-4, IL-9 and IL-10.
Our results demonstrated that IL-9 and IL-10 were produced by
distinct CD3+ cells (ﬁgure 4C). Moreover, invariant NKT cells
did not produce IL-9 (ﬁgure 4C). Taken together these results
suggest that in patients with UC, IL-9 is mainly produced by
CD3+ cells that do not coexpress IL-10 or IL-4.
Human IL-9-secreting peripheral blood lymphocytes express
the gut homing markers α4 and β7 integrin
To investigate the potential of peripheral blood lymphocytes to
produce IL-9 along with other cytokines whose levels have been
found to be altered in UC (eg, IL-4, IL-10, IL-13, IL17A/F,
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TGF-β), we isolated and stimulated blood lymphocytes from UC
or healthy controls for two days with anti-CD3/anti-CD28 anti-
bodies. Stimulated UC lymphocytes produced signiﬁcantly more
IL-9 compared with unstimulated cells from the same patients
(ﬁgure 5A). Cells from non-inﬂammatory controls that were sti-
mulated under the same conditions produced signiﬁcantly less
Figure 1 Interleukin (IL)-9 overexpression in mucosal biopsies from patients with UC. Patients were scored according to histopathological criteria
for inﬂammation activity in UC23 as described in materials and methods. (A) Quantitative assessment of IL-4, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-21,
IFN-γ, TGF-β and TNF-α mRNA expression in sigmoid colon and rectum biopsies of patients with UC with no (IS0) (n=7), mild (IS1) (n=11; for IL-9,
n=16), moderate (IS2) (n=9; for IL-9, n=27) and severe (IS3) (n=16; for IL-9, n=25) disease and healthy controls (n=10) shown as fold induction
(left). Quantitative assessment of IL-9 mRNA expression in patients with UC and ileal (n=9) and colonic biopsies (n=6) of patients with Crohn’s
disease with moderate and severe inﬂammation and healthy controls (right). CD, Crohn’s disease. IS, inﬂammation score. (B) Correlation of IL-9
mRNA levels with levels for IL-6, IL-13, IL-17A, IL-4, IL-10, IL-21, IFN-γ, TGF-β, TNF-α and S100A8 mRNA in patients with UC with detectable IL-9
levels (n=13 for cytokines, n=18 for S100A8). Data are shown as mean values±SEM (*p<0.05, **p<0.01, ***p<0.001, n.s., not signiﬁcant) using
GraphPad Prism 5.
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IL-9 when compared with stimulated UC cells, whereas
unstimulated control cells did not produce detectable levels of
IL-9. Furthermore, we found that stimulated peripheral blood
lymphocytes from patients with UC having C reactive protein
levels <5 mg/L produced signiﬁcantly less IL-9 when compared
with patients with UC with C reactive protein levels >5 mg/L
Figure 2 Interleukin (IL)-9 expression by CD3+ T cells is increased in the gut of patients with UC with severe inﬂammation. (A) Immunoﬂuorescence
staining for IL-9 of parafﬁn sections of human mucosal tissues from controls and patients with UC with mild (IS1) and severe (IS3) inﬂammation.
(B) Quantiﬁcation of the IL-9-expressing cells in 7 high-power ﬁelds per patient (n=5 per group). (C) Immunoﬂuorescence two-colour staining for IL-9 and
CD3 of parafﬁn sections of mucosal tissues from controls, patients with mild (ie, IS1) and severe inﬂamed (ie, IS3) UC (inset: higher magniﬁcation).
Representative cells coexpressing IL-9 and CD3 are marked with an arrowhead. Scale bars, all 50 mm. (D) Quantiﬁcation of the CD3+ IL-9-expressing cells
in 7 high-power ﬁelds per patient (n=5 per group). (E) Percentage of the CD3+ IL-9-expressing and CD3− IL-9-expressing cells in 7 high-power ﬁelds per
patient (n=5 per group). Data are shown as mean values±SEM (**p<0.01, ***p<0.001) using GraphPad Prism 5. IS, inﬂammation score.
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(ﬁgure 5A). IL-13 levels increased the most between healthy
individuals and patients with UC, although IL-10 (5.8 times)
and TGF-β (4.6 times) levels were also considerably upregu-
lated. Moderate correlations were observed between IL-9 and
IL-13 (R=0.69; p<0.001) and between IL-9 and IL-10 levels
(R=0.52; p<0.01), respectively (ﬁgure 5B). The occurrence of
IL-9 producing CD3+ cells in the gut and the peripheral blood
raised the question of whether peripheral IL-9-expressing T cells
might home to the gut in UC. To address this experimentally,
we analysed the expression of α4 and β7 integrins in Th9
polarised blood CD3+ T cells. We found that 16% of the integ-
rin α4+ and 30% of the β7+CD3+ cells expressed IL-9 (ﬁgure
5C) suggesting that circulating IL-9-expressing cells might
become recruited into the inﬂamed gut by their surface expres-
sion of α4 and β7 integrins.
IL-9R overexpression is functionally relevant for
antiapoptotic signals in UC
Based on previous data indicating increased IL-9R expression on
PMN from patients with asthma,25 we sought to investigate the
IL-9R expression proﬁle on peripheral blood and gut-inﬁltrating
PMN in patients with UC. We could demonstrate the presence
of the IL-9R on cytospins by immunoﬂuorescence (see online
supplementary ﬁgure S1B). Using ﬂow cytometry, we found that
PMN from patients with UC expressed signiﬁcantly more IL-9R
compared with controls (ﬁgure 6A). Furthermore, CD16− eosi-
nophils also expressed IL-9R, albeit at a lower level (ﬁgure 6A).
To study functional aspects of IL-9 signalling, PMN were iso-
lated from the peripheral blood and stimulated with various
doses of recombinant IL-9. We observed a dose-dependent IL-8
production (ﬁgure 6B). This effect could be inhibited by pre-
blocking IL-9R signalling in PMN from patients with UC
(ﬁgure 6B). Granulocyte macrophage colony stimulating factor
(GM-CSF)-stimulated PMN from patients with UC that served
as stimulation controls produced signiﬁcantly more IL-8 com-
pared with control PMN (ﬁgures 6B). Traditionally, PMN were
considered to be short-lived terminally differentiated cells
whose life span can be substantially increased by proinﬂamma-
tory stimuli.26 To investigate the ability of IL-9 to modulate
PMN survival, we incubated cells with different doses of IL-9.
Figure 3 In UC lesions, interleukin (IL)-9 is coexpressed with the Th9 transcription factors interferon regulatory factor 4 (IRF4) and PU.1.
(A) Determination of IRF4 and PU.1 mRNA expression in the sigmoid colon and rectum biopsies of patients with UC with no (IS0) (n=7), mild (IS1) (n=11),
moderate (IS2) (n=9) and severe (IS3) (n=16) inﬂammation and healthy controls (n=10), respectively. (B, C) Two-colour immunoﬂuorescence staining of
parafﬁn sections from control (left) and severe inﬂamed (ie, IS3) (middle) mucosal tissues for IL-9 and IRF4, and IL-9 and PU.1. Representative cells
coexpressing IL-9 and IRF4 or PU.1 are indicated by arrowheads. Scale bars, all 50 mm (inset: higher magniﬁcation). Quantiﬁcation of the IRF4+ IL-9+ and
PU.1+ IL-9+ cells in patients with UC and controls is provided (right). Cells were counted in 7 high-power ﬁelds per patient (n=5 per group). Data are
shown as mean values±SEM (*p<0.05, **p<0.01, ***p<0.001) using GraphPad Prism 5. IS, inﬂammation score.
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Figure 4 In patients with UC, IL-9 is induced by interferon regulatory factor 4 (IRF4) but is not coexpressed with IL-4 or IL-10. (A) Dot plots of
representative CD3+ IL-9-expressing blood lymphocytes from patients with UC under non-polarised and Th9 polarised conditions (left). Histogram
indicates the percentage of IL-9-expressing cells among gated CD3+ IRF4+ cells in Th9 polarised cells. Quantiﬁcation of pooled data from four
patients is shown for CD3+ IRF4+ gated cells. (B) Representative confocal microscopy image of human mucosal tissue from patients with UC with
severe inﬂammation (ie, IS3). Cells coexpressing IL-9, CD3 and IRF4 are marked with an arrowhead. Scale bars, all 50 mm. Quantiﬁcation of data
from 7 high-power ﬁelds indicating the percentage of IRF4+ IL-9+, IRF4+ IL-9−, IRF4− IL-9+ and IRF4− IL-9− among CD3+ cells is provided (right).
(C) Representative ﬂow cytometry data of IL-9 production by CD3 and Vα24-Jα18 (the invariable NKT cell marker) populations in the lamina propria
(top). IL-10-production, IL-9-production and IL-4-production in distinct populations of CD3+ cells in the lamina propria from inﬂamed UC lesions
(bottom). Quantiﬁcation of data pooled from ﬁve patients with inﬂamed UC lesions (right). IS, inﬂammation score.
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Figure 5 Production of cytokines by cultured peripheral blood lymphocytes and expression of gut homing markers in Th9 polarised cells.
(A) Enzyme-linked immunosorbent assay detection of IL-9 levels produced by unstimulated and anti-CD3/anti-CD28-stimulated peripheral blood
lymphocytes from patients with UC (n=33) and non-inﬂammatory controls (n=7) (left). Patients with UC were grouped according to their C reactive protein
value into C reactive protein <5 mg/L (n=16) and C reactive protein >5 mg/L (n=17). (B) Enzyme-linked immunosorbent assay levels for IL-4, IL-10, IL-13,
IL-17A/F and TGF-β in stimulated blood cells from patients with UC (n=25) and controls (n=7) are shown (top left). Correlations of IL-9 levels with levels
for IL-4, IL-10, IL-13, IL-17A/F and TGF-β in patients with UC (n=25) are provided. Data are shown as mean values±SEM (*p<0.05, **p<0.01,
***p<0.001, n.s., not signiﬁcant) using GraphPad Prism 5. (C) Representative ﬂow cytometry data of the expression of IL-9 in CD3+ α4 integrin+ and
CD3+ β7 integrin+ cells, respectively, in whole blood IL-9-expressing lymphocytes (Isotype—grey, dashed line; stained sample—black line) (left).
Quantiﬁcation indicates the percentages of IL-9-expressing cells in the gated α4 integrin+ and β7 integrin+ cells of four patients with UC (right).
Inﬂammatory bowel disease
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Figure 6 IL-9-induced IL-8 production and delayed apoptosis of IL-9R-overexpressing polymorphonuclear leucocytes (PMN) in patients with UC.
(A) Representative ﬂow cytometry histogram of IL-9R expression on blood granulocytes from patients with UC and healthy controls is shown (left).
Quantiﬁcation of the IL-9R staining in UC (n=13) and controls (n=12) (second from left). Representative dot plot of gated granulocytes based on their
CD16 expression and side scatter (SSC) properties (second from right, top). IL-9R expression in PMN and in eosinophils is shown in a representative ﬂow
cytometry histogram (second from right, bottom). Quantiﬁcation of the IL-9R expression levels in PMN and eosinophils (n=4) (right). EOS, Eosinophils.
(B) IL-9-induced dose-dependent production of IL-8 in supernatants of stimulated PMN from patients with UC and controls (n=5 per group) (left). IL-8
production in PMN preparations from UC by stimulation with 50 ng/mL IL-9 and the use of an anti-hIL-9R blocking antibody (n=4) (middle). IL-8
production in GM-CSF-stimulated PMN from controls (n=9) and patients with UC (n=11) (right). (C) Quantiﬁcation of apoptosis rates in PMN stimulated
with different doses of IL-9 (0, 0.5, 5, 50 ng/ml) (left); correlation between IL-9-induced IL-8 levels and IL-9-induced apoptosis resistance after 18 h (right)
(n=5). Data are shown as mean values±SEM (*p<0.05, **p<0.01, ***p<0.001) using GraphPad Prism 5. (D) Two-colour immunoﬂuorescence staining of
parafﬁn sections of human mucosal tissues showing a crypt abscess with IL-9R and myeloperoxidase double positive PMN (inset: higher magniﬁcation).
Representative cells coexpressing IL-9R and myeloperoxidase are marked with an arrowhead. Scale bars, all 50 mm.
Inﬂammatory bowel disease
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After 18 h, PMN were stained with Annexin V and Propidium
iodide and apoptosis rates were determined (see online supple-
mentary ﬁgure S1C). IL-9-induced signals rendered PMN resist-
ant to apoptosis in a dose-dependent manner (ﬁgure 6C) which
correlated well with levels of IL-8 production by these cells
(ﬁgure 6C). Importantly, crypt abscesses from patients with
severe inﬂammation were dominated by IL-9R+ and myeloper-
oxidase+ PMN, suggesting a functional role for IL-9 signalling
in PMN in UC (ﬁgure 6D).
IL-9 induces STAT5 phosphorylation in primary
gut epithelial cells
Extensive analysis of gut specimens revealed that cells within
the lamina propria and the epithelial layer expressed the IL-9R
(ﬁgure 7A). More speciﬁcally, epithelial cells populating crypts
above the ‘+4’ position expressed IL-9R in patients with mild
(ie, IS1) and severe (ie, IS3) inﬂammation as well as controls
(ﬁgure 7A) suggesting that IL-9R expression is not Paneth cell
or stem cell related. Quantiﬁcation of the IL-9R+ cells in the
lamina propria together with epithelium indicated signiﬁcantly
increased numbers in severe UC (ie, IS3) compared with mild
inﬂammation (ie, IS1) and with controls, respectively, as well as
between mild inﬂammation and controls (ﬁgure 7A). To further
investigate the IL-9R-expressing cells in situ, epithelial cells
from resected tissues were stained with antibodies to epithelial
cell adhesion molecule (EpCAM), CD3 and IL-9R. EpCAM+
epithelial cells showed consistent IL-9R expression levels
(ﬁgure 7B upper histogram) whereas intraepithelial CD3+ lym-
phocytes (middle histogram) and CD3− EpCAM−-cells (lower
histogram) showed marginal IL-9R expression. Moreover,
EpCAM+ epithelial cells of patients with UC with severe inﬂam-
mation (ie, IS3) expressed IL-9R to a higher extent than controls
(ﬁgure 7B). To gain more insights into the mechanistic function
of IL-9 on the gut epithelium, we stimulated freshly isolated epi-
thelial cells with IL-9. Control preparations were either incu-
bated in medium alone or preincubated for 60 min with an
anti-hIL-9R blocking antibody before IL-9 was added. After
60 min of IL-9 stimulation we observed signiﬁcantly more
pSTAT5 in cells receiving IL-9 compared with cells incubated in
medium only whereas preblocked preparations had intermediate
levels of STAT5 activation (ﬁgure 7C).
Blocking IL-9R accelerates wound healing
To functionally address the role of IL-9 in the gut physiology,
we used Caco-2 monolayers as a model of the gut epithelium.
First we demonstrated that these cells express the IL-9R
(ﬁgure 8A). To exclude a possible proapoptotic effect of IL-9,
we stained for active caspases using staurosporin-induced (2 mM
for 12 h) apoptosis as a control (ﬁgure 8B). Cells were then
seeded in culture-inserts and after reaching conﬂuence, an artiﬁ-
cial gap was produced by removing the insert from the culture
vessel. Cells were then incubated for 60 min either with an
anti-hIL-9R blocking antibody or with medium alone and
100 ng/mL IL-9 was added for additional 18 h. Control prepara-
tions received only medium. Interestingly, IL-9 delayed Caco-2
cells’ growth in a signiﬁcant manner whereas IL-9R blockade
limited the potential of IL-9 to interfere with cell growth
(ﬁgure 8C) providing evidence for a potential pathogenic role
of IL-9 in the context of mucosal healing in UC.
DISCUSSION
The better understanding of molecular mechanisms driving
chronic gut inﬂammation has led over the past two decades to
novel therapeutic strategies with great impact for the current
management of IBD.27–29 However, despite spectacular suc-
cesses mainly attributable to the anti-TNF therapy,27 29 not all
patients respond to the newer drugs and about a third of the
responders relapse within a short time.27 Further studies are
therefore needed to identify novel therapeutic molecules in
IBD.27 30 In the present study, we set out to investigate the role
of IL-9 in the pathogenesis of UC. Our results demonstrated
that IL-9 is involved in promoting inﬂammation in UC by acting
on IL-9R overexpressing gut epithelial cells and PMN.
Furthermore, IL-9 should be considered as a potential novel
marker for monitoring the severity of disease as IL-9 levels cor-
related with the severity of disease and with levels of the sys-
temic proinﬂammatory S100A8 protein in UC. Nevertheless,
since current anticytokine strategies mainly focus on targeting
the Th1 or Th2 pathways, interfering with IL-9 signalling might
emerge as starting point for speciﬁc therapeutic approaches.
Since its conception, the Th1/Th2 paradigm has dominated
the immunological thinking for almost two decades.31 However,
due to recent advances in the ﬁeld of transcriptional regulation
of immune responses, many of the functions attributed to either
the Th1 or the Th2 populations are increasingly becoming asso-
ciated with the newly discovered Th177 and/or Th912 15 cells.
Whereas the role of IL-17 is relatively well characterised,2 7 the
role of IL-9 in UC has not yet been investigated. In the present
study, we therefore addressed the role of IL-9 and the key Th9
transcription factors IRF419 and PU.120 in UC disease
pathogenesis.
Interestingly, we found signiﬁcantly increased expression of
IL-9 mRNA levels in patients with severe inﬂammation compared
with controls. Furthermore, the relative expression of IL-9 best
correlated with that of S100A8, high levels of which were previ-
ously reported in active UC.32 Among investigated cytokines,
IL-9 mRNA levels best correlated with those of IL-6 and IL-17A,
whose altered expression was previously linked to UC.21 22
To extend our ﬁndings to the protein level in situ, we stained
parafﬁn gut biopsies and resected tissues from patients with UC
with mild and severe disease as well as controls. In patients with
UC with severe disease IL-9 expression was signiﬁcantly
increased compared with mild disease UC and controls, respect-
ively. In addition, IL-9 expression was largely restricted to
lamina propria cells and two-colour immunoﬂuorescence stain-
ings indicated that CD3+ T cells accounted for more than 75%
of the IL-9-expressing cells in IS3 lesions. To clarify the nature
of the CD3− IL-9-expressing cells, we stained for IL-9 and mye-
loperoxidase as a marker of PMN since these cells have been
reported to be able to produce IL-933 and often dominate the
picture in acute UC lesions.23 Interestingly, PMN did produce
IL-9 in UC lesions (see online supplementary ﬁgure S1). In
mice, IL-9 production has also been associated with type 2
innate lymphoid cells.14 15 Since no antibodies are currently
available to stain these cells in sections of human bowel we
cannot completely exclude the fact that innate lymphoid cells
produce IL-9 in UC. Nevertheless, our data clearly demonstrate
that CD3+ cells are the main producers of IL-9 in UC.
To gain more functional insights into IL-9 actions in UC, we
performed two-colour immunoﬂuorescence stainings for IL-9
and IRF4 or PU.1, the two key transcription factors of Th9
cells.19 20 We found signiﬁcantly more IL-9+ IRF4+ and to a
lesser extent IL-9+ PU.1+ cells in severe disease compared with
mild disease and controls, respectively. Furthermore, the
co-localisation of IL-9 and IRF4 in individual cells suggests a
multifaceted role of IRF4 in the pathogenesis of IBD. Although
previous data deﬁned a critical role for IRF4 in the IL-6- and
IL-17-dependent gut pathology,21 22 our present results indicate
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Figure 7 In gut epithelial cells IL-9 activates STAT5. (A) IL-9R immunoﬂuorescence of parafﬁn sections of human mucosal tissues from control and
patients with UC with mild (ie, IS1) and severe (ie, IS3) inﬂammation (left, middle). Scale bars, all 50 mm. Quantiﬁcation of the IL-9R+ cells in 7
high-power ﬁelds per patient (n=5 per group) (right). (B) Epithelial cells isolated from resected tissue were analysed by ﬂow cytometry. Cells were
stained with EpCAM to gate for epithelial cells (EpCAM+) and with CD3 to gate for intraepithelial lymphocytes (CD3+) and the double negative
population (CD3− EpCAM−) (left). Representative ﬂow cytometry data for IL-9R expression in one patient with UC IS3 and control in those gated cell
populations is shown (middle). Representative panel of EpCAM+ cells from one patient with severely inﬂamed UC (ie, IS3) and one control are
shown (right, top). Quantiﬁcation of EpCAM+ IL-9R+ cells (%) (right, bottom). Resected tissues from 14 patients (10 controls, 4 patients with UC
IS3) were analysed by ﬂow cytometry. (C) Epithelial cells were stimulated with 100 ng/mL IL-9 with or without 1 mg/ml anti-hIL-9R pretreatment and
investigated for pSTAT5 expression. Representative ﬂow cytometry panel of EpCAM+ IL-9R+ cells from one control is shown (left). Quantiﬁcation of
EpCAM+ IL-9R+ pSTAT5+ cells of stimulated controls (n=4) are shown as fold induction as compared with steady state (right). Data are shown as
mean values±SEM (*p<0.05, **p<0.01, ***p<0.001, n.s., not signiﬁcant) using GraphPad Prism 5. IS, inﬂammation score.
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that IRF4 might exert alternative and probably synergistic actions
by modulating the IL-9-driven inﬂammation in the gut. To more
precisely address the functional role of IRF4 in the generation of
IL-9 in the context of UC, we investigated the ability of IL-4 and
TGF-β to induce IL-9 expression in Th9 polarised blood lympho-
cytes. Consistent with previously reported rates of IL-9 expres-
sion in polarised human Th9 cells34–36 we detected about 6%
IL-9-expressiong cells among Th9 polarised UC lymphocytes.
Figure 8 Interleukin (IL)-9-induced delay in wound healing assayed by intestinal epithelial Caco-2 cell scratch assays. (A) IL-9R
immunoﬂuorescence staining of Caco-2 cells grown on chamber slides. Scale bars, all 50 mm. (B) Active caspase staining of Caco-2 cells 48 h after
addition of 100 ng/mL IL-9. Staurosporin (2 mM for 12 h) served as a positive control. Representative caspase-positive cells are marked with an
arrowhead. A second independent experiment showed similar results. (C) 100 ng/mL IL-9, with or without 1 mg/mL anti-hIL-9R pretreatment, was
added to Caco-2 cells grown to conﬂuence on culture-inserts and cells were investigated in duplicates in three independent wound healing
experiments. Representative pictures of one experiment are shown (left, middle) and quantiﬁcation of lesion size (%) as indicated (right). Data are
shown as mean values±SEM (*p<0.05, **p<0.01, ***p<0.001) using GraphPad Prism 5.
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Among polarised cells, about 25% of the IRF4+ cells expressed
IL-9. We conﬁrmed CD3, IL-9 and IRF4 colocalisation in situ by
confocal imaging consistent with the idea that IRF4 acts as a key
transcription factor for the generation of IL-9 in the inﬂamed gut
of patients with UC.
In mice, Th9 cells can produce IL-9 and IL-10.16 17
Moreover, invariable NKT-derived IL-9 has been shown to
protect animals in a mouse model of colitis in an
IL-4-dependent manner.24 We addressed this scenario in patients
with UC and found that lamina propria cells from patients with
UC did not express IL-9 and IL-10 strengthening the point that
human Th9 cells do not coexpress IL-10. 34 35 Since invariable
NKT cells from the lamina propria of patients with UC did not
express IL-9, and IL-4 was not coexpressed with IL-9 in our
setting, the observed results24 could be explained by differences
between iNKT cells from humans and mice.
We next focused on the ability of peripheral blood lympho-
cytes from patients with UC to produce IL-9. Stimulated cells
produced signiﬁcantly higher levels of IL-9 compared with
unstimulated cells from the same patients with UC. Moreover,
lymphocytes from patients with UC with C reactive protein
levels >5 mg/L produced signiﬁcantly more IL-9 compared with
those from patients with levels <5 mg/L, suggesting that IL-9
levels might potentially represent a systemic inﬂammatory
marker along with C reactive protein or S100A8 in UC.1
Moreover, UC lymphocytes produced increased levels of IL-10,
IL-13, IL-17A, TGF-β and to a lesser extent IL-4. However,
except for IL-13 and IL-10 whose levels moderately correlated
with those of IL-9, we found no further correlations between
IL-9 levels and levels of the other investigated cytokines. In line
with our results, recent studies found that human Th9 cells do
not produce IL-10 or signature cytokines of the other Th
subsets whereas IL-9 production precedes and coordinates
the secretion of other cytokines in cultured human lympho-
cytes.34 35 Having identiﬁed a peripheral source of
IL-9-expressing cells, we further wondered whether these cells
have the potential to home to the gut by investigating their
surface expression of α4 and β7 integrins, two regulators of
lymphocyte trafﬁcking into the colon.37 About 16% and 30%
of the CD3+ α4+ and CD3+ β7+ cells, respectively expressed
IL-9. Taken together these data indicate that in human UC IL-9
is mainly produced by CD3+ cells which are distinct from their
murine counterparts with respect to IL-4 and IL-10 production.
Nevertheless, our ﬁndings might be clinically relevant when tar-
geting the recruitment of the IL-9-expressing cells by the use of
therapeutic anti-integrin antibodies.38 39
The role of granulocytes in UC has been conclusively demon-
strated: these cells and their derived products including pro-
teases, reactive oxygen species and chemokines are present in
high numbers in the inﬂamed gut and are a common feature of
crypt abscesses, particularly during disease ﬂare-ups.1 However,
the ﬁne molecular mechanisms governing the actions of these
short-lived cells in UC still need further characterisation. The
presence of the IL-9R on PMN has been discussed controver-
sially. A ﬁrst study reported that PMN express IL-9R mRNA,40
whereas a later one stated that PMN were not capable to do
so.41 Subsequently, it was shown that peripheral blood PMN
from patients with asthma express IL-9R mRNA in signiﬁcantly
higher amounts compared with PMN from healthy controls.25
The authors found that lung inﬁltrating PMN also stained posi-
tive for the IL-9R and by showing that IL-9 speciﬁcally induced
IL-8 production in a dose-dependent manner, they demon-
strated its functional role.25 Accordingly, our ﬂow cytometry
demonstrated that IL-9R is signiﬁcantly overexpressed on the
surface of circulating PMN from patients with UC as compared
with control cells. Upon stimulation with either GM-CSF or
IL-9, patients’ PMN released high amounts of the antiapoptotic
chemokine IL-8. IL-8 production proved to be dependent on
the IL-9 concentration and anti-hIL-9R antibodies could block
IL-8 release. In addition, our immunoﬂuorescence two-colour
stainings for myeloperoxidase and IL-9R in mucosa from
patients with UC demonstrated that inﬁltrating PMN keep on
expressing IL-9R, providing a possibly highly relevant and
totally unanticipated functional mechanism for the
PMN-mediated gut pathology in situ. We hypothesised that
PMN encountering the proinﬂammatory milieu—for example,
GM-CSF,42 TNF-α43 and IL-9 among others—in the gut of
patients with UC become apoptosis-resistant. By producing
more IL-8, PMN further increase their half-life43 44 and
reinforce the recruitment of additional leucocytes to support
chronic inﬂammation and establish crypt abscesses. To test our
hypothesis experimentally, we incubated PMN with IL-9
and observed a dose-dependent inhibition of apoptosis.
Moreover, this correlated with the ability of IL-9 to induce IL-8
production in PMN cultures suggesting that in UC the antiapop-
totic effect of IL-9 could be due to its ability to trigger IL-8
production.44
We further hypothesised that IL-9 actions on IL-9R-bearing
gut epithelial cells are comparable with those on IL-9R-bearing
lung epithelial cells.45 Indeed, epithelial cells from severe lesions
of patients with UC expressed higher IL-9R levels than controls.
Flow cytometry analysis of isolated epithelial cells indicated the
presence of IL-9R on epithelial cells whereas intraepithelial
CD3+ T cells showed only marginal expression. To functionally
address the role of the IL-9R signalling in gut epithelial cells, we
stimulated freshly isolated epithelial cells with IL-9 and per-
formed intracellular staining for pSTAT5, a main signalling
partner of the IL-9R.46 Interestingly, pSTAT5 was signiﬁcantly
increased in IL-9 versus non-stimulated cells. Preblocking IL-9R
signalling resulted in decreased pSTAT5 levels. To functionally
address the role of IL-9 in the process of mucosal healing that
accompanies epithelial gut restoration, we evaluated its effect on
Caco-2 cell monolayers.47 IL-9 signiﬁcantly delayed the growth
of the Caco-2 cells into the gap in scratch assays. Taken together
these results indicate that IL-9 signalling may activate epithelial
cells in the UC lesions and block the restitution of the gut epi-
thelium in established lesions.
Based on our present results we propose the following scen-
ario triggered by IL-9 in UC: IL-9 produced by CD3+ T cells in
the inﬂamed gut activates either one or more of the following
pathways: (1) epithelial cells’ activation by pSTAT5-mediated
signalling in IL-9R overexpressing cells which may release proin-
ﬂammatory cytokines to recruit leucocytes in situ; (2) activation
of inﬁltrating PMN followed by the inhibition of their apop-
tosis. Long-lived PMN could reinforce further recruitment of
activated lymphocytes48 and eosinophils49 by producing more
IL-8 and/or may directly damage the gut epithelium by releasing
reactive oxygen species, matrix metalloproteinases and various
cytokines including IL-9 itself; (3) IL-9 may block the mucosal
healing process leading to the perpetuation of the inﬂammation
and the establishment of chronic lesions.
In conclusion, our study demonstrates that IL-9 has pleio-
tropic functions in UC by inducing STAT5 signalling in gut epi-
thelial cells, interfering with the mucosal healing process,
inducing IL-8 production and increasing resistance to apoptosis
in PMN. Alongside other potential cytokine targets,30 our
results strongly recommend IL-9 as a possible disease severity
marker and a promising future therapeutic candidate in UC.
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